Heart Failure

Heart failure occurs when the heart cannot pump as much blood as the body requires. This ineffective pumping can lead to enlargement of the heart as the myocardium works harder pump the same amount of blood. Heart failure may be caused by defects in the myocardium, such as an a heart attack infarct, or due to structural issues such as severe heart valve regurgitation. Heart failure can be divided into HF with preserved ejection fraction (HFpEF), and HF with reduced ejection fraction (HFrEF). The disease is further divided into four New York Heart Association (NYHA) classes. Stage IV heart failure is when the heart is completely failing and requires a heart transplant or hemodynamic support from a left ventricular assist device (LVAD).

RSS icon

FDA fast-tracks heart failure medication omecamtiv mecarbil

Omecamtiv mecarbil, a cardiac myosin activator being manufactured by Amgen and Cytokinetics to treat heart failure with reduced ejection fraction, has been granted a Fast Track designation by the FDA.

May 14, 2020
risk-1945683_960_720.jpg

Rheumatoid arthritis associated with greater risk of HF, especially when CRP levels are high

Rheumatoid arthritis is associated with a greater risk of heart failure, according to new findings published in the Journal of the American Heart Association. The risk increases even more when patients have higher levels of C-reactive protein, a telltale sign of severe inflammation.  

May 12, 2020

Mavacamten shows potential for treating hypertrophic cardiomyopathy in EXPLORER-HCM trial

Mavacamten has demonstrated value as a treatment option for patients with obstructive hypertrophic cardiomyopathy (HCM), according to results from the EXPLORER-HCM phase III clinical trial.

May 12, 2020
Large peridevice leaks after left atrial appendage occlusion (LAAO) are incredibly rare and not associated with a greater risk of adverse outcomes, according to new research published in JACC: Clinical Electrophysiology.[1] Smaller residual links are more common, however, and associated with a risk of thromboembolic and bleeding events.

FDA approves Farxiga for HF patients with reduced ejection fraction

The FDA has approved a new treatment option, Farxiga oral tablets, for adult heart failure patients with reduced ejection fraction.

May 6, 2020
""

TTVR improves outcomes for patients with severe tricuspid regurgitation

Transcatheter edge-to-edge tricuspid valve repair (TTVR) is an effective treatment option for patients with severe tricuspid regurgitation (TR), according to a new study published in JACC: Heart Failure.

April 13, 2020

Statins reduce risk of developing HF from breast cancer therapies

Key chemotherapy treatments are known to have a negative impact on cardiovascular health, even leading to heart failure (HF) in some patients.

March 23, 2020
Diabetes

HF patients with type 2 diabetes can safely be treated with liraglutide

Liraglutide, a common medication used to treat type 2 diabetes (T2D), is safe to use for heart failure (HF) patients, according to new findings published in the Journal of the American College of Cardiology.

March 18, 2020
Smog

Heart-failure patients lose years of life when air pollution is a neighbor

Long-term daily exposure to air pollution carrying fine particulate matter poses a significant risk of all-cause mortality for people with heart failure (HF).

March 16, 2020
Displaying 393 - 400 of 912

Around the web

Health Imaging
New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Radiology Business
What does radiology have to do with climate change?

Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."

Design by Adaptive Theme
Trimed Popup
Trimed Popup